**Core Concept**
Haloperidol, a typical antipsychotic, is a dopamine D2 receptor antagonist. Its use in schizophrenia is based on the dopamine hypothesis, which suggests that an overactive dopaminergic system contributes to the pathophysiology of the disorder. However, haloperidol's blockade of dopamine receptors in the nigrostriatal pathway can lead to extrapyramidal side effects (EPS).

**Why the Correct Answer is Right**
The patient's symptoms of restlessness, fidgetiness, irritability, and inability to sit still at one place are characteristic of akathisia, a type of EPS. Akathisia is thought to result from the blockade of dopamine receptors in the brain, which disrupts the normal function of the nigrostriatal pathway. This disruption leads to an imbalance in motor control, causing the patient to experience restlessness and a compelling urge to move. The correct treatment strategy for akathisia involves the use of beta-blockers, such as propranolol, which can help alleviate these symptoms.

**Why Each Wrong Option is Incorrect**
**Option A:** Increasing the dose of haloperidol would exacerbate the EPS and worsen the patient's symptoms, making this option incorrect.
**Option B:** Switching to an atypical antipsychotic may not necessarily address the acute symptoms of akathisia, and may take several weeks to take effect, making this option incorrect.
**Option C:** Adding a benzodiazepine may provide some temporary relief but is not a recommended treatment for akathisia, as it does not address the underlying cause of the symptoms, making this option incorrect.

**Clinical Pearl / High-Yield Fact**
Beta-blockers, such as propranolol, are a first-line treatment for akathisia, and can provide rapid relief from symptoms. A mnemonic to remember this is "Beta-blockers Beat Akathisia."

**Correct Answer:** B. Switching to an atypical antipsychotic, such as risperidone or olanzapine, is the most appropriate treatment strategy for akathisia.